Due to increasing safety concerns, puberty blockers have been permanently prohibited in the UK for youngsters seeking gender-affirming therapy.
According to a study published by the Commission on Human Medicines (CHM), there is “currently an unacceptable safety risk in the continued prescription of puberty blockers to children.”
In order to guarantee the safety of young individuals going through medical transition, the panel has suggested indefinite limits until further study is done.
In his remarks, Health and Social Care Secretary Wes Streeting stressed the need to “act with caution” and “follow the expert advice” when dealing with this “vulnerable group of young people.”
“Children’s healthcare must always be evidence-led,” he said. The existing treatment and prescription process for gender dysphoria.
And incongruence poses an intolerable safety risk to children and adolescents, according to the independent expert Commission on Human Medicines.
“The paucity of data supporting these medical procedures also sparked safety concerns in Dr. Cass’s evaluation. When it comes to this vulnerable group of youth, we must exercise prudence.
